Stuart Seropian, MD

• Alexa Siddon
• Alfred Lee
• Amer Zeidan
• Ami Rubinowitz
• Barbara Burtness
• Brett King
• Brian Smith
• Charles Dela Cruz
• Christina Price
• Christopher Tormey
• Clemente Britto-Leon
• Daniel Zelterman
• Darko Pucar
• David Ferguson
• David J. Hur
• Deborah Proctor
• Dhanpat Jain
• Diane Krause
• Edward Snyder
• Erin Medoff
• Fangyong Li
• Francine Foss
• Frederick Altice
• Geliang Gan
• Geoffrey Chupp
• George Goshua
• Hamid Mojibian
• Harry Aslanian
• Insoo Kang
• Iris Isufi
• Jean Bolognia
• Jeanne Hendrickson
• Jeffrey Topal
• Jennifer McNiff
• Jeremy Kortmansky
• Joachim Baehring
• John Greg Howe
• Juan Vasquez
• Judith Meadows
• Julie Baker
• Kenneth B. Roberts
• Lauren A. Baldassarre
• Lauren Pischel
• Lohith Gowda
• Lydia Aoun-Barakat
• Lynn D. Wilson
• Manoj M Pillai
• Maricar Malinis
• Marie Robert
• Marie-Louise Landry
• Mario Sznol
• Marwan Mikheal Azar
• Merceditas Villanueva
• Michael Cecchini
• Michael Girardi
• Mina Xu
• Naftali Kaminski
• Natalia Neparidze
• Nikolai Podoltsev
• Noffar Bar
• Patricia LoRusso
• Richard Bucala
• Richard Formica
• Richard Torres
• Rory Shallis
• Samuel Katz
• Scott Huntington
• Shana Gleeson
• Sheela Shenoi
• Steffen Huber
• Stephanie Halene
• Sudhir Perincheri
• Tae Kon Kim
• Terri Parker
• Thomas Prebet
• Venkata Boddupalli
• Wei Wei
• Xiaomei Ma
• Yanhong Deng
• Zachary Harris

Hematologic Diseases; Hematopoietic Stem Cells; Hodgkin Disease; Leukemia; Lymphocytes; Lymphoma; Lymphoma, Non-Hodgkin; Plasma Cells; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic

Cancer; Clinical Trials

• Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2021, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.
• Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet. Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/S2352-3026(20)30429-4.
• Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.Gupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion And Apheresis Science : Official Journal Of The World Apheresis Association : Official Journal Of The European Society For Haemapheresis 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.
• Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma, Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
• Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion.Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-system Pharmacy : AJHP : Official Journal Of The American Society Of Health-System Pharmacists 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
• Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias.Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.
• Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.
• Life Expectancy After Allogeneic Stem Cell Transplant-In It for the Long Haul?Gowda L, Seropian S. Life Expectancy After Allogeneic Stem Cell Transplant-In It for the Long Haul? JAMA Oncology 2021, 7: 1611-1613. PMID: 34499090, DOI: 10.1001/jamaoncol.2021.3674.
• Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Annals Of Hematology 2022, 101: 1145-1147. PMID: 34686913, DOI: 10.1007/s00277-021-04702-w.
• Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat.Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma, Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.
• Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.
• Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 755-781. PMID: 32502987, DOI: 10.6004/jnccn.2020.0026.
• Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
• Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
• Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma, Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.
• Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2019, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
• The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN).Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease : An Official Journal Of The Transplantation Society 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.
• Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.
• NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 245-254. PMID: 29523663, DOI: 10.6004/jnccn.2018.0013.
• Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2018, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
• Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2017, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.
• Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.
• Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient.Anderson A, McManus D, Perreault S, Lo YC, Seropian S, Topal JE. Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. Medical Mycology Case Reports 2017, 17: 11-13. PMID: 28580237, PMCID: PMC5447657, DOI: 10.1016/j.mmcr.2017.05.004.
• Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 608-638. PMID: 28476741, DOI: 10.6004/jnccn.2017.0064.
• Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis.Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis. Circulation. Cardiovascular Imaging 2016, 9 PMID: 27682238, DOI: 10.1161/CIRCIMAGING.116.004770.
• Autologous Stem Cell Mobilization in the Age of Plerixafor.Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma, Myeloma & Leukemia 2016, 16: 411-6. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.
• Expression of CD30 as a biomarker to predict response to brentuximab vedotin.Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-8. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.
• The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2016, 51: 273-6. PMID: 26479982, DOI: 10.1038/bmt.2015.247.
• Hodgkin lymphoma, version 2.2015.Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 554-86. PMID: 25964641, PMCID: PMC4898052, DOI: 10.6004/jnccn.2015.0075.
• Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-51. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.
• Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. The Journal Of Clinical Investigation 2015, 125: 2677-89. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/JCI81229.
• Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant.Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. Journal For Immunotherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.
• Disorders of LymphocytesLacy J, Seropian, S, Disorders of Lymphocytes, Andreoli: in Cecil Essentials of Medicine, 9th ed. 2014
• Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British Journal Of Haematology 2014, 167: 141-4. PMID: 24888971, DOI: 10.1111/bjh.12944.
• Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation.Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation. Palliative & Supportive Care 2014, 12: 53-61. PMID: 24169207, DOI: 10.1017/S1478951513000552.
• LeukemiaRoberts K, Seropian S, Marks, P, Leukemia, Perez and Brady’s In Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
• Total-Body and HemiBody IrradiationRoberts K, Chen, Z, Seropian S. Total-Body and HemiBody Irradiation, Perez and Brady’s Principles and Practice of Radiation Oncology, Halperin E, Perez C, and Brady L eds. Sixth edition. 2013
• LymphomaIsufi I, Seropian S, Lymphoma, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
• Plasma Cell DisordersSeropian S, Isufi I, Plasma Cell Disorders, Oncology in Primary Care. Rose, MG, Devita VT, Lawrence TS, Rosenberg SA, 1st edition, 2013
• Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2013, 48: 646-50. PMID: 23165491, DOI: 10.1038/bmt.2012.218.
• Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high-dose granulocyte colony-stimulating factor.Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high-dose granulocyte colony-stimulating factor. Journal Of Clinical Apheresis 2012, 27: 235-41. PMID: 22566214, DOI: 10.1002/jca.21232.
• Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults.Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-25. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.
• Prospective evaluation of acute graft-versus-host disease.Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, Jain D. Prospective evaluation of acute graft-versus-host disease. Digestive Diseases And Sciences 2012, 57: 720-5. PMID: 22011927, DOI: 10.1007/s10620-011-1938-x.
• Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clinical Lymphoma, Myeloma & Leukemia 2011, 11: 267-72. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.
• Disseminated fusarium infection with muscle involvement.King BA, Seropian S, Fox LP. Disseminated fusarium infection with muscle involvement. Journal Of The American Academy Of Dermatology 2011, 65: 235-7. PMID: 21679835, DOI: 10.1016/j.jaad.2009.12.034.
• Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nature Reviews. Clinical Oncology 2010, 7: 415-20. PMID: 20404855, DOI: 10.1038/nrclinonc.2010.40.
• Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. American Journal Of Hematology 2009, 84: 599-600. PMID: 19650144, DOI: 10.1002/ajh.21478.
• Outpatient high-dose melphalan in multiple myeloma patients.Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007, 47: 115-9. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.
• Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum.Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. Journal Of The American Academy Of Dermatology 2005, 53: 591-601. PMID: 16198778, DOI: 10.1016/j.jaad.2005.06.015.
• New Approaches to allografting in non-Hodgkin's lymphoma.Seropian S, Cooper DL. New Approaches to allografting in non-Hodgkin's lymphoma. Progress in Oncology, 2004 Jones and Bartlett.
• Images in neuro-oncology. Large B-cell lymphoma.Baehring J, Cooper D, Seropian S, Bannykh S. Images in neuro-oncology. Large B-cell lymphoma. Journal Of Neuro-oncology 2004, 67: 189. PMID: 15072466, DOI: 10.1023/b:neon.0000021952.37526.49.
• A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-7. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.
• Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003, 32: 763-9. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.
• Hodgkin's DiseaseSeropian S, Cooper DL. Hodgkin's Diseases in Annual of Lymphoid Malignancies. Cavelli F, Longo D eds. 2000
• Autologous Stem Cell TransplantationCooper DL, Seropian S, Autologous Stem Cell Transplantation, in Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg S eds. 6th edition, 2000.
• Isolation and flow cytometric analysis of T-cell-depleted CD34+ PBPCs.Debelak J, Shlomchik MJ, Snyder EL, Cooper D, Seropian S, McGuirk J, Smith B, Krause DS. Isolation and flow cytometric analysis of T-cell-depleted CD34+ PBPCs. Transfusion 2000, 40: 1475-81. PMID: 11134567, DOI: 10.1046/j.1537-2995.2000.40121475.x.
• Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.Marshall NA, Howe JG, Formica R, Krause D, Wagner JE, Berliner N, Crouch J, Pilip I, Cooper D, Blazar BR, Seropian S, Pamer EG. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516.
• High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2000, 11: 665-72. PMID: 10942053, DOI: 10.1023/a:1008396525292.
• Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis.Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, Seropian SE, McDonald GB. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology (Baltimore, Md.) 2000, 32: 1265-71. PMID: 11093733, DOI: 10.1053/jhep.2000.20067.
• Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation 1999, 24: 1253-8. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.
• Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.
• Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.Salloum E, Jillella AP, Nadkarni R, Seropian S, Hu GL, D'Andrea E, Zelterman D, Cooper DL. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-12. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.
• Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant.Seropian S, Ferguson D, Salloum E, Cooper D, Landry ML. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplantation 1998, 22: 507-9. PMID: 9733277, DOI: 10.1038/sj.bmt.1701354.
• HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders.McGuirk JP, Seropian S, Cooper D. HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. The Cancer Journal From Scientific American 1998, 4: 278-86. PMID: 9815289.
• Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 1174-1185. PMID: 35007144, PMCID: PMC8987226, DOI: 10.1200/JCO.21.01755.
• NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network : JNCCN 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.
• Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma.Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2022 PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.